Literature DB >> 18726161

New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy.

Frank C Brosius1.   

Abstract

Progression of diabetic nephropathy (DN) is manifested by gradual scarring of both the renal glomerulus and tubulointerstitial region. Over the past several years, the general understanding of the pathogenic factors that lead to renal fibrosis in DN has expanded considerably. In this review, some of the important factors that appear to be involved in driving this fibrosing process are discussed, with special emphasis on newer findings and insights. It is now clear that multiple cell types in the kidney contribute to progressive fibrosis in DN. New concepts about bradykinin, TGF-beta and eNOS signaling as well as JAK/STAT activation and the central role of inflammation in both glomerular and tubulointerstitial fibrosis are discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18726161      PMCID: PMC3776415          DOI: 10.1007/s11154-008-9100-6

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN: 1389-9155            Impact factor:   6.514


  78 in total

1.  Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice.

Authors:  Hui John Zhao; Suwan Wang; Huifang Cheng; Ming-zhi Zhang; Takamune Takahashi; Agnes B Fogo; Matthew D Breyer; Raymond C Harris
Journal:  J Am Soc Nephrol       Date:  2006-09-13       Impact factor: 10.121

2.  Cyclo-oxygenase-2 inhibition attenuates the progression of nephropathy in uninephrectomized diabetic rats.

Authors:  Radko Komers; Jessie N Lindsley; Terry T Oyama; Sharon Anderson
Journal:  Clin Exp Pharmacol Physiol       Date:  2007 Jan-Feb       Impact factor: 2.557

3.  Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease.

Authors:  Wendy C Burns; Stephen M Twigg; Josephine M Forbes; Josefa Pete; Christos Tikellis; Vicki Thallas-Bonke; Merlin C Thomas; Mark E Cooper; Phillip Kantharidis
Journal:  J Am Soc Nephrol       Date:  2006-08-16       Impact factor: 10.121

Review 4.  Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update.

Authors:  K O Alsaad; A M Herzenberg
Journal:  J Clin Pathol       Date:  2007-01       Impact factor: 3.411

5.  Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes.

Authors:  Gregory Proctor; Tao Jiang; Mieko Iwahashi; Zhuowei Wang; Jinping Li; Moshe Levi
Journal:  Diabetes       Date:  2006-09       Impact factor: 9.461

6.  Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy.

Authors:  Holger Schmid; Anissa Boucherot; Yoshinari Yasuda; Anna Henger; Bodo Brunner; Felix Eichinger; Almut Nitsche; Eva Kiss; Markus Bleich; Hermann-Josef Gröne; Peter J Nelson; Detlef Schlöndorff; Clemens D Cohen; Matthias Kretzler
Journal:  Diabetes       Date:  2006-11       Impact factor: 9.461

7.  Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse.

Authors:  W Huang; Y Gallois; N Bouby; P Bruneval; D Heudes; M F Belair; J H Krege; P Meneton; M Marre; O Smithies; F Alhenc-Gelas
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

8.  Senescence-associated phenotypes in Akita diabetic mice are enhanced by absence of bradykinin B2 receptors.

Authors:  Masao Kakoki; Catherine M Kizer; Xianwen Yi; Nobuyuki Takahashi; Hyung-Suk Kim; C Robert Bagnell; Cora-Jean S Edgell; Nobuyo Maeda; J Charles Jennette; Oliver Smithies
Journal:  J Clin Invest       Date:  2006-04-06       Impact factor: 14.808

9.  The effect of angiotensin II receptor blockade on an end-stage renal failure model of type 2 diabetes.

Authors:  Makoto Mizuno; Toshio Sada; Mikio Kato; Yasuo Fukushima; Hideki Terashima; Hiroyuki Koike
Journal:  J Cardiovasc Pharmacol       Date:  2006-10       Impact factor: 3.105

Review 10.  Role of the JAK/STAT signaling pathway in diabetic nephropathy.

Authors:  Mario B Marrero; Amy K Banes-Berceli; David M Stern; Douglas C Eaton
Journal:  Am J Physiol Renal Physiol       Date:  2006-04
View more
  58 in total

1.  Genetic variation in the matrix metalloproteinase genes and diabetic nephropathy in type 1 diabetes.

Authors:  Masahiko Kure; Marcus G Pezzolesi; G David Poznik; Pisut Katavetin; Jan Skupien; Jonathon S Dunn; Josyf C Mychaleckyj; James H Warram; Andrzej S Krolewski
Journal:  Mol Genet Metab       Date:  2011-01-14       Impact factor: 4.797

2.  Epigenetic histone methylation modulates fibrotic gene expression.

Authors:  Guangdong Sun; Marpadga A Reddy; Hang Yuan; Linda Lanting; Mitsuo Kato; Rama Natarajan
Journal:  J Am Soc Nephrol       Date:  2010-10-07       Impact factor: 10.121

3.  Cathepsin D protects renal tubular cells from damage induced by high glucose independent of its enzymatic activity.

Authors:  Feng Du; Tian Wang; Si Li; Xin Meng; Hai-Yan Zhang; De-Tian Li; Zhen-Xian Du; Hua-Qin Wang
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

Review 4.  Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy.

Authors:  Nestor F Gonzalez-Cadavid; Jacob Rajfer
Journal:  Nat Rev Urol       Date:  2010-03-09       Impact factor: 14.432

5.  Janus kinase 2/signal transducer and activator of transcription 3 inhibitors attenuate the effect of cardiotrophin-like cytokine factor 1 and human focal segmental glomerulosclerosis serum on glomerular filtration barrier.

Authors:  Mukut Sharma; Jianping Zhou; Jean-François Gauchat; Ram Sharma; Ellen T McCarthy; Tarak Srivastava; Virginia J Savin
Journal:  Transl Res       Date:  2015-03-16       Impact factor: 7.012

6.  Genetic basis of nondiabetic end-stage renal disease.

Authors:  Barry I Freedman; Rulan S Parekh; W H Linda Kao
Journal:  Semin Nephrol       Date:  2010-03       Impact factor: 5.299

Review 7.  Glycemic memories and the epigenetic component of diabetic nephropathy.

Authors:  Samuel T Keating; Assam El-Osta
Journal:  Curr Diab Rep       Date:  2013-08       Impact factor: 4.810

8.  The ubiquitin-like protein FAT10 mediates NF-kappaB activation.

Authors:  Pengfei Gong; Allon Canaan; Bin Wang; Jeremy Leventhal; Alexandra Snyder; Viji Nair; Clemens D Cohen; Matthias Kretzler; Vivette D'Agati; Sherman Weissman; Michael J Ross
Journal:  J Am Soc Nephrol       Date:  2009-12-03       Impact factor: 10.121

9.  Poly(ADP-ribose) polymerase (PARP) inhibition counteracts multiple manifestations of kidney disease in long-term streptozotocin-diabetic rat model.

Authors:  Hanna Shevalye; Roman Stavniichuk; Weizheng Xu; Jie Zhang; Sergey Lupachyk; Yury Maksimchyk; Viktor R Drel; Elizabeth Z Floyd; Barbara Slusher; Irina G Obrosova
Journal:  Biochem Pharmacol       Date:  2009-11-27       Impact factor: 5.858

10.  Diabetic nephropathy.

Authors:  Themis Zelmanovitz; Fernando Gerchman; Amely Ps Balthazar; Fúlvio Cs Thomazelli; Jorge D Matos; Luís H Canani
Journal:  Diabetol Metab Syndr       Date:  2009-09-21       Impact factor: 3.320

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.